Studies towards the identification of potent, selective and bioavailable thrombin inhibitors.

[1]  D. Janus,et al.  The discovery of orally available thrombin inhibitors: studies towards the optimisation of CGH1668. , 1998, Bioorganic & medicinal chemistry letters.

[2]  B. Kaiser,et al.  THROMBIN AND FACTOR XA INHIBITORS , 1998 .

[3]  M. Ghorab,et al.  Improvement of the biological performance of oral anticoagulant drugs. 2. Dicumarol. , 1997, Die Pharmazie.

[4]  J. Vacca,et al.  Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy. , 1997, Journal of medicinal chemistry.

[5]  W. Ripka,et al.  Chapter 8. Antithrombotics/Serine Proteases , 1997 .

[6]  D A Smith,et al.  Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics , 1996, Medicinal research reviews.

[7]  D. Veber,et al.  Inhibition of Thrombin by Peptides Containing Lysyl-α-Keto Carbonyl Derivatives , 1995, Thrombosis and Haemostasis.

[8]  Kimball Sd.  Challenges in the development of orally bioavailable thrombin active site inhibitors. , 1995 .

[9]  J. Hirsh,et al.  Advances in Antithrombotic Therapy: Novel Agents , 1995, Thrombosis and Haemostasis.

[10]  T. Urano,et al.  The physiological aspects of fibrinolysis. , 1994, Thrombosis research.

[11]  J. Maraganore,et al.  Thrombin structure and function: why thrombin is the primary target for antithrombotics. , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.